<SEC-DOCUMENT>0001193125-16-425700.txt : 20160111
<SEC-HEADER>0001193125-16-425700.hdr.sgml : 20160111
<ACCEPTANCE-DATETIME>20160111070100
ACCESSION NUMBER:		0001193125-16-425700
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160111
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160111
DATE AS OF CHANGE:		20160111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		161335025

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d121214d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;11, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2, Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;11, 2016, Amarin Corporation plc, or the
Company, issued a press release providing preliminary unaudited fourth quarter and annual 2015 financial guidance and its financial outlook for 2016. A copy of the Company&#146;s press release is furnished herewith as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information set forth under Item&nbsp;2.02 and in Exhibit 99.1 is intended to be furnished and shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial
Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January 11, 2016</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;11, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January 11, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d121214dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g121214ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>2015 Net Product Revenue Estimated to be Approximately $26.0 million for the Fourth Quarter and $80 Million for the Full Year, Exceeding
Prior Guidance </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Anticipate Full-Year 2016 Net Product Revenues Between $105 million and $120 million, Commercial Operations
Positioned to be Cash Flow Positive Entering 2017 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, January&nbsp;11, 2016 &#151; Amarin Corporation plc (NASDAQ:
AMRN), today provided a business update, including preliminary unaudited fourth quarter and full year 2015 revenue and 2016 revenue outlook. Amarin plans to discuss these results and expectations for the coming year with investors in conjunction
with the 34<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Annual J.P. Morgan Healthcare Conference in San Francisco, California. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Preliminary (Unaudited) 2015 Revenue and Year-end Cash Results </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Fourth quarter 2015: </B>Net product revenue estimated to be approximately $26.0 million, which represents growth of approximately: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">58% over fourth quarter 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">22% sequentially over third quarter 2015; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8% over the upper range of Amarin&#146;s prior guidance. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Full-Year 2015: </B>Net product
revenue is expected to be approximately $80.0 million reflecting growth of approximately: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">48% compared to 2014; 50% growth compared to 2014 including licensing revenue. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Cash:
</B>Cash and cash equivalents at December&nbsp;31, 2015 were approximately $107.0 million compared to $119.5 million at year-end 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Additional
2015 Operational Progress </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>REDUCE-IT: </B>Enrollment reached approximately 7,900 patients as of December&nbsp;31, 2015,
representing 99% of the patients targeted for enrollment in this prospective cardiovascular outcomes study, the first such study ever conducted to evaluate the effect of treating patients who despite statin therapy have elevated triglyceride levels
and the first cardiovascular outcomes study to test a high, 4-gram per day dose of a pure-EPA omega-3 prescription product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amarin made substantial
progress in its commercial growth and outcomes study in 2015, including obtaining the authority to significantly expand the scope of information we can use to promote Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent
ethyl) capsules. We intend to build on this progress in 2016 by continuing to educate healthcare professionals regarding the efficacy and safety of Vascepa, growing revenues and executing on our cardiovascular outcomes study,&#148; commented John F.
Thero, President and Chief Executive Officer. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>2016 Objectives and Financial Outlook </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Commercial Operations:</B> Amarin is intently focused on growing revenue in 2016 and anticipates being able to further increase Vascepa
product revenues through productivity improvements without expanding its sales force. The company expects total net product revenue (excluding licensing revenue) of between $105 and $120 million in 2016, which is expected to position Amarin to enter
2017 cash flow positive from commercial operations, excluding REDUCE-IT and other research and development (R&amp;D) expenses not required to sustain current commercial operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Revenue growth in 2016 is expected to remain variable from quarter to quarter. In particular, as experienced in each of the past two years,
revenues in the first quarter of 2016 are expected to be impacted by seasonal factors such as the effect of new year insurance deductibles on consumer behavior regarding prescription refills, particularly for therapies treating asymptomatic, chronic
conditions, such as Vascepa. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>REDUCE-IT: </B>The continued progression of REDUCE-IT in a cost-effective manner is a key priority for
Amarin heading into 2016. The timing of cumulative primary cardiovascular events in this study continues to track to prior estimates supporting onset of the predefined target
(1,612<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;cumulative event in 2017 and publication of results in 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Based on
historical event rates in the study, Amarin expects to attain 60% of the target aggregate number of cardiovascular events during the first half of 2016, triggering a pre-specified interim review by the independent data monitoring committee (DMC) of
the trial&#146;s efficacy and safety results. After the 60% target has been achieved, additional time is required by the contract research organizations to finish collecting and preparing data for transfer to and analysis by the DMC. As is typical
for large-scale, multi-national studies, this process is expected to take several months. Also as is typical for outcomes studies and based on the design of REDUCE-IT, management continues to expect that the study will run to completion rather than
being stopped early for overwhelming efficacy at the interim look. Amarin will remain blinded to the interim and ongoing results throughout the study. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The company anticipates that R&amp;D expenses, excluding non-cash costs in 2016 will remain relatively consistent with 2015 levels with the
majority of such spending devoted to the ongoing REDUCE-IT trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin plans to provide further details regarding its 2015 results and 2016 outlook in
connection with the publication of its 2015 audited financial results in late February. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About Amarin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin&#146;s clinical program includes commitment to an ongoing outcomes study.
Amarin&#146;s first product, Vascepa&reg; (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules, known in scientific literature as AMR101, is a
highly pure-EPA&nbsp;omega-3 prescription product in a 1 gram capsule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indications and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of VASCEPA on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for VASCEPA </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt; 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt; 3% and greater than placebo.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse events and product complaints may be reported by calling </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">1-855-VASCEPA or
the&nbsp;FDA&nbsp;at 1-800-FDA-1088. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT&nbsp;<U>WWW.VASCEPA.COM</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the&nbsp;United States Food and Drug Administration&nbsp;(FDA) as an adjunct to diet to reduce triglyceride levels in
adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 500 mg/dL) hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by the&nbsp;FDA. Nothing in
this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the&nbsp;FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking
statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the future commercialization of Vascepa; expectations
regarding Vascepa sales and resulting revenue amounts for the fourth quarter of 2015 and for the years ended December&nbsp;31, 2015 and 2016; expectations related to Amarin&#146;s 2016 financial outlook and potentially entering 2017 as cash flow
positive from commercial operations; including expectations for continued enrollment, event rates, interim data review and results announcements in Amarin&#146;s REDUCE-IT cardiovascular outcomes study; expectations regarding the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continued effect and scope of the court-expanded ability to promote Vascepa and to educate healthcare professionals regarding the efficacy and safety of Vascepa; expectations related to the
interim and final outcome of the REDUCE-IT study and the successful completion of the REDUCE-IT study; statements regarding quarterly changes and seasonal effects on Vascepa sales; and statements regarding the potential efficacy, safety and
therapeutic benefits of Vascepa. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission,
Amarin&#146;s ability to effectively commercialize Vascepa will depend in part on its ability to continue to effectively finance its business (including the REDUCE-IT study), efforts of third parties, its ability to create market demand for Vascepa
through education, marketing and sales activities, to achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price,
to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or
projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that historical REDUCE-IT clinical trial enrollment and randomization rates may not
be predictive of future results and related cost may increase beyond expectations; the risk that regulatory reviews may impact the current design of the REDUCE-IT study or cause a change in strategic direction with respect to continuation of the
study; the risk that future litigation, court decisions and interpretation and interactions with regulatory authorities may impact Vascepa marketing and sales rights and efforts; the risk that Vascepa may not show clinically meaningful effects in
REDUCE-IT or support regulatory approvals for cardiovascular risk reduction; the risk associated with pending litigation; and the risk that patents may not be upheld in patent litigation and applications may not result in issued patents. A further
list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form
10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or circumstances or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of other information about Amarin
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website (<U>www.amarincorp.com</U>), our
investor relations website (<U>http://www.amarincorp.com</U>&nbsp;/investor-splash.html), including but not limited to investor presentations and investor FAQs,&nbsp;Securities and Exchange Commission&nbsp;filings, press releases, public conference
calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on
these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these
channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin contact information: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathryn McNeil </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908)&nbsp;719-1315 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graham Morrell </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (646)&nbsp;378-2954 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>gmorrell@troutgroup.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source:&nbsp;Amarin Corp. Plc
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee Davies </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Makovsky </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (212)&nbsp;508-9651 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ldavies@makovsky.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g121214ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g121214ex99_1pg001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /P$I P$1  (1 0,1 ?_$ -<   (#  $% 0
M       *" D+!P$" P0&!0$  P$! 0$! 0            8'!0@$ P$"$
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M (I10/\ O!A-TGIFIIJ"M1IBE'@IJ9)<.]:C/'TDQ'+RT[54_OE\XNO%*1P
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M_9XV3A] YOR6/X0H$?V_@#54^$(E<JK[M/>J$C7Q_=&>E7]6$G=G?-^UWM5
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MFIUY=0\I]SVUJ)/23.+(TVEEM+2/92 !U0GUYR#]WC9-_;=DO^H##5;^$?\
M$:O[M'>N$/7W^$9^DK^K"6.R$/\ YG[1P'_[,X+X_P#J96PU8[Z1[GJI?[%?
MU#$WMI_?V?O$_6$;.YOKF_*$?6.N//FF>V?R1T0=GY;H34WJ?\U]L0_LOHO]
M7,PZKUH__,JW[U?>F)Y<?^]F.A'<88TZB_3RP5U)MO$[@K,T81G)(@XF,89+
MCVC=2V8LO!$!(PL4"Y4 #J,5S ",DP,8$)!H)DS\# F<D\T]J"LTY<4UE&?
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M5<JYZ^/B:2>5$^S#H'I)CA#SB'[H^TC_ !&6'^[6:UH?"3&ZU/W2?K1Y-?\
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M&?.'#5&3K?6(2![DJB)8?9O9;/[+*% Z<T]MN%-/Z:?^+'E1Z!?2(%=N#;S
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*/08L<U@QJ1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
